FDA approves Anoro Ellipta
The U.S. Food and Drug Administration have approved GlaxoSmithKline's Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive pulmonary disease.
Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist that can be used once a day, the first to combine two long-acting bronchodilators into a single inhaler. It is expected to be available in the first quarter of 2014.
“We believe Anoro Ellipta will be an important treatment option for appropriate patients with COPD. … This approval is a significant achievement for GSK,” said Darrell Baker, SVP & Head, GSK Global Respiratory Franchise.
Testing for Anoro Ellipta included seven clinical studies with almost 6,000 patients with COPD.